Long-term survival following multimodal therapy for lung cancer with hepatic metastasis: a case report

肺癌肝转移患者接受多模式治疗后的长期生存:病例报告

阅读:1

Abstract

BACKGROUND: The liver serves as a predominant metastatic site in advanced lung cancer, with patients developing hepatic metastases demonstrating particularly dismal prognosis and a median survival of approximately 5 months. Currently, no consensus has been established regarding optimal therapeutic strategies for lung cancer with liver metastases. CASE PRESENTATION: A patient with advanced lung cancer and oligometastatic liver metastases achieved significant tumor regression in both pulmonary and hepatic lesions following combined immunotherapy and chemotherapy. Subsequent radiofrequency ablation was performed for the liver metastasis, while surgical resection of the primary lung lesion resulted in pathological complete response (pCR). The patient has maintained long-term survival without evidence of disease recurrence. CONCLUSIONS: For patients with advanced lung cancer and oligometastatic liver metastases demonstrating favorable response to combined immunotherapy and chemotherapy, consolidative surgical resection with adjunctive liver-directed local therapy may be considered, potentially conferring long-term survival benefits.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。